Direct answers, cited
BPC-157 FAQ
Twenty-five questions answered from the published BPC-157 literature — recovery, safety, dosage, oral use, and the FDA 503A legal status. Each answer states what the evidence supports and what it does not.
Recovery and efficacy
Does BPC-157 build muscle?
Published evidence does not show muscle-building. The muscle literature is about recovery from crush injury and corticosteroid-impaired healing in rats [5][6], not hypertrophy. Online muscle-building claims are unsupported.
Does BPC-157 help with muscle growth?
No published study demonstrates muscle growth. Rodent work shows accelerated functional recovery after muscle crush injury [5], which is repair, not growth.
Can BPC-157 heal arthritis?
No controlled human trial supports an arthritis indication. One small uncontrolled case series reported reduced knee pain after intra-articular injection [8]; tendon, ligament, and bone healing have been studied mostly in rodents.
Has anyone used BPC-157 to heal an injury?
Human data are limited to three small uncontrolled pilots: an intravenous safety pilot, an intra-articular knee-pain series, and an intravesical interstitial-cystitis study [9][8][11]. The bulk of injury-healing evidence is preclinical (rodent).
How long does BPC-157 take to work?
No validated human time-to-effect exists. Animal healing studies run over days to weeks with once-daily dosing [1][5].
How long does it take for BPC-157 to kick in?
Unestablished in humans. The peptide's elimination half-life is under 30 minutes in animal pharmacokinetics [2], but tissue-repair timelines in studies span weeks.
BPC-157 vs TB-500: what is the difference?
They are different peptides studied in separate literatures; BPC-157's repair effects are most consistently linked to VEGFR2-driven angiogenesis [3]. This site summarizes only BPC-157 research.
Can BPC-157 help with weight loss?
No. Weight-loss claims are not supported by the published literature and should be treated skeptically.
Identity and effects
What does BPC-157 do in the body?
In animal models it is described as cytoprotective, with repair effects most consistently linked to angiogenesis via VEGFR2-Akt-eNOS signaling and modulation of the nitric-oxide system [3].
Is BPC-157 a growth hormone?
No. It is a synthetic 15-amino-acid peptide. It has been reported to up-regulate growth-hormone-receptor expression in tendon fibroblasts [7], but it is not itself a growth hormone.
Does BPC-157 work immediately?
Onset is not established in humans. Animal studies dose once daily over days to weeks [1]; there is no validated human time-to-effect.
How does BPC-157 make you feel?
Subjective effects are not characterized in controlled human research. Central-nervous-system effects (serotonergic, antidepressant-like) are reported only in rodent models [7].
Safety and interactions
Does BPC-157 damage the liver?
No liver damage was seen in the small human intravenous pilot, which recorded no biomarker changes [9], and rodent work actually reports hepatoprotection in injury models [12]. Long-term human safety remains unknown.
Is BPC-157 hard on the kidneys?
The two-person intravenous pilot recorded no measurable renal biomarker changes [9]. There is no large human safety dataset, so kidney effects are not fully characterized.
Can BPC-157 mess with your heart?
The human intravenous pilot saw no cardiac biomarker changes [9]; rodent cardiac models report protection [7]. Human cardiac-safety data are essentially absent.
Is BPC-157 bad for the heart?
No harm was reported in the small human pilot, and animal heart-disturbance models describe cytoprotective effects [7][9]. This is not a substitute for controlled human cardiac-safety data, which do not exist.
Can BPC-157 cause liver damage?
Published animal and pilot-human data do not show liver damage; recent rat work reports liver protection in a distant-organ-injury model [12]. Absence of long-term human data means the full picture is unknown.
What should you not mix with BPC-157?
Interaction data in humans are absent. Rodent studies report BPC-157 counteracting NSAID (diclofenac) toxicity, but this is an animal finding, not a human co-administration guideline.
Dosage, duration, and route
How long should I stay on BPC-157?
There is no validated human duration. Animal studies vary by model [1][5]; this is research-context information, not a usage recommendation.
What happens when you stop taking BPC-157?
No withdrawal or discontinuation effects are characterized in humans because no long-term human studies exist.
Can BPC-157 be taken orally?
It is termed a stable gastric pentadecapeptide because it is reported stable in gastric juice, which motivates oral interest [7], but formal human oral pharmacokinetics are not established.
Does oral BPC-157 work?
Rodent gastrointestinal studies use intragastric and peroral routes, but there is no human oral-efficacy trial and no validated human oral pharmacokinetics [7], so oral effectiveness in people is unproven.
Legal status and access
Is BPC-157 legal?
BPC-157 is not an FDA-approved drug, and FDA placed it in 503A Category 2 — bulk substances that may present significant safety risks — effective with FDA's September 29, 2023 update, meaning it is not within FDA's enforcement-discretion policy for 503A compounding [16]. It is also prohibited in sport at all times by the World Anti-Doping Agency. BPC-157 is individually listed on the July 23-24, 2026 PCAC agenda as a substance under evaluation for the 503A bulks list [18] — a scheduled discussion, not a change in legal status. This is general information, not legal advice.
Can you get BPC-157 from a compounding pharmacy?
Legally compounded access runs through a licensed-prescriber evaluation (telehealth can be the front-end channel) to a patient-specific prescription, dispensed by a 503A pharmacy or sourced from a 503B outsourcing facility [17]. But a compounder may use an ingredient only if it is eligible under the bulk-substance rules, and a Category 2 substance flagged for significant safety risks is not eligible for routine 503A compounding while that status stands [16]. This is general information, not an offer to supply.
What is the FDA 503A status of BPC-157?
BPC-157 (evaluated as "BPC-157 (free base)" and "BPC-157 acetate") is in 503A Category 2, effective with FDA's September 29, 2023 nominated-substances update, on stated concerns including potential immunogenicity for certain routes and peptide-impurity and characterization complexity [16]. Category 2 substances are not covered by FDA's enforcement-discretion policy. BPC-157 is on the July 23-24, 2026 PCAC agenda as a substance being considered for the 503A bulks list [18] — an evaluation step, not a listing decision.